Compare FCBM & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCBM | LAB |
|---|---|---|
| Founded | N/A | 1999 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 393.3M | 326.2M |
| IPO Year | 2026 | 2008 |
| Metric | FCBM | LAB |
|---|---|---|
| Price | $12.97 | $0.69 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.35 |
| AVG Volume (30 Days) | 91.6K | ★ 1.8M |
| Earning Date | N/A | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.54 |
| EPS | ★ 0.44 | 0.26 |
| Revenue | N/A | ★ $101,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.63 |
| P/E Ratio | $29.39 | ★ $2.65 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.17 | $0.63 |
| 52 Week High | $13.40 | $1.72 |
| Indicator | FCBM | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 60.04 | 47.52 |
| Support Level | $12.50 | $0.63 |
| Resistance Level | $13.40 | $1.02 |
| Average True Range (ATR) | 0.24 | 0.03 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 54.29 | 61.73 |
First Carolina Financial Services Inc is a bank holding company. The company's activities consist of managing and owning the Bank and its direct and indirect subsidiaries. The Bank provides commercial banking, payment, consumer banking, and wealth management services to small and medium-sized businesses, individuals, professionals, as well as institutions of higher education. It has four primary lines of business: Commercial Banking, Payments, Consumer Banking and Wealth Management. The reportable segments are Community Banking and BM Tech. The majority of revenue is derived from the Community Banking segment, which comprises activities of a traditional banking institution, gathering deposits and originating loans for portfolio in its respective primary market areas.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.